Five proposed biosimilars planned for development in Europe
The extended partnership agreement between Alvotech and Advanz Pharmaceutical includes a biosimilar candidate to Entyvio® (vedolizumab).
List view / Grid view
The extended partnership agreement between Alvotech and Advanz Pharmaceutical includes a biosimilar candidate to Entyvio® (vedolizumab).
MSD has announced long-term maintenance results from GO-COLITIS.
16 February 2016 | By Victoria White
A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.
9 February 2016 | By Victoria White
The committee was unable to accept eculizumab as it was "not considered to represent an effective use of NHS Scotland’s resources"...
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
26 June 2015 | By Victoria White
The EC has approved Simponi (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA)...
11 June 2015 | By Victoria White
Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR...
26 May 2015 | By Victoria White
CHMP has adopted a positive opinion of Simponi for the treatment of adults with severe active non-radiographic axial spondyloarthritis...
19 November 2014 | By MSD
Application for approval of new indication for golimumab has been filed with the European Medicines Agency...